
Dec 31 (Reuters) - Corcept Therapeutics Inc CORT.O:
CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM
CORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDA
CORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVAL